Noile-Immune Biotech Inc. announced that Noile-Immune received the following notification regarding the license agreements with Takeda): - Takeda has decided to terminate the license agreement for NIB102 (TAK102) and NIB103 (TAK103), thereby returning the rights for the development and commercialization of NIB102 and NIB103 to Noile-Immune. - The reason for the termination of the license agreement for NIB102 and NIB103 is due to a strategic shift in Takeda's development portfolio towards allogeneic cell therapies, and is not related to any concerns about the safety or efficacy of NIB102 and NIB103. As a consequence of this termination, Noile-Immune will hold the rights of NIB102 and NIB103.

Noile-Immune is going to discuss with Takeda regarding the transition of ongoing trials, transfer of the obtained data, handling of intellectual property rights, and settlement of termination fee paid by Takeda, so as to explore future options. It should be noted that the termination fee may vary depending on the details of the development costs incurred by Takeda to date and may not be applicable.